8-K - InMed Pharmaceuticals Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

InMed Pharmaceuticals reported financial results for Q2 FY2026, ended December 31, 2025, and provided a business update on its drug development programs. The company disclosed a decrease in revenue from its BayMedica subsidiary and a material negative impact expected from pending U.S. legislation.

Key Takeaways

1Reported Q2 FY2026 revenue of $0.8 million, a 26% decrease from $1.1 million in the same quarter last year.

2Cash, cash equivalents, and short-term investments were $7.0 million as of December 31, 2025, down from $11.1 million on June 30, 2025.

3U.S. legislation H.R. 5371, if enacted on November 12, 2026, would have a material negative impact on the BayMedica subsidiary.

4The company expects its cash will be sufficient to fund operations into the fourth quarter of calendar year 2026.

5Advanced preclinical studies for INM-901, a drug candidate for Alzheimer's disease, and INM-089 for dry age-related macular degeneration.

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act,

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News rele

Exhibits Only

Source Document

Results of Operations

Second Quarter Fiscal 2026

Metric	Value	Prior Period
Sales	$820.2K	$1.1M
Gross profit	$184.2K	$460.9K
Research and development	$630.6K	$895.2K
General and administrative	$1.6M	$1.7M
Net loss	$2.0M	$2.6M
Net loss per share	$0.51	$3.64

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1